IMMUNOGENETIC FACTORS IN THE PROGNOSIS OF HIV INFECTIONS

由于感染了导致获得性免疫缺陷综合症的病毒 （艾滋病）、艾滋病毒，如通过存在针对该病毒的特异性抗体来检测， 病毒，发生在越来越多的人谁继续有 没有或只有非常初步的症状的实际临床表现 感染时间延长，免疫遗传因素可能有助于 不同个体控制病毒影响的能力。许多 这些人在休斯顿受到监视， 临床症状和体征的发展，有些正在接受治疗， 实验方案旨在评估是否确定 抗病毒药物可以防止临床症状的发展， 一些迹象和一些正在治疗的实验方案， 评估某些抗病毒药物是否可以预防 出现临床体征和/或增加T4细胞计数。各种 研究表明，这些抗体阳性的人中， 出现免疫缺陷综合征的临床表现， 年他们还表明，遗传和免疫参数， 可以预测哪些临床表现（即，卡波西肉瘤vs 机会性感染），包括组织相容性 型、补体同种异型、细胞表面表型谱和体外 免疫功能反应。 该项目的具体目的将是收集 组织相容性、补体同种异型、细胞表面表型和 一个大的群体的免疫功能数据与抗体， 艾滋病毒，并将这些遗传/免疫反应因素与临床 包括对各种安慰剂治疗的反应的过程 协议.处于感染可能反应的各个阶段的患者， 只要能得到关于 首次感染或首次出现抗体的可能数据。 每年将招募约150例患者用于研究。细胞 表面表型，包括T4和T8细胞百分比以及双重 染色T8-Leu 7、T8-T10和T8-Dr，以及相对免疫反应 PHA、con A、美洲商陆有丝分裂原和同种异体细胞将在 每例患者每年至少3次。临床研究数据 与皮肤试验反应有关的内容也将纳入 分析。

Since infection with the virus causing Acquired Immunodeficiency Syndrome (AIDS), HIV, as detected by the presence of specific antibodies to that virus, occurs in an increasing number of individuals who continue to have no or only very preliminary symptoms of actual clinical manifestations of the infection for prolonged periods, immunogenetic factors may contribute to the ability of different individuals to control virus effects. Many such individuals are being monitored in Houston for the possible development of clinical symptoms and signs and some are being treated in experimental protocols designed to evaluate whether or not certain antiviral agents may prevent the development of clinical symptoms and signs and some are being treated in experimental protocols designed to evaluate whether or not certain antiviral agents may prevent the development of clinical signs and/or increase T4 cell counts. Various studies indicate that some of these antibody positive individuals will develop clinical manifestations of the immunodeficiency syndrome each year. They also suggest that genetic and immunological parameters that may predict which clinical manifestations (i.e., Kaposi's sarcoma vs opportunistic infections) they might develop include histocompatibility type, complement allotype, cell surface phenotype profile, and in vitro immune function responses. The specific purpose of this project will be to collect histocompatibility, complement allotype, cell surface phenotype and immune function data for a large group of individuals with antibodies to HIV and to correlate these genetic/immune response factors to clinical course including responses to various prophylatic drug treatment protocols. Patients at all stages of possible responses to infection will be recruited as long as information is available as to the approximate likely data of initial infection or first appearance of antibody. Approximately 150 patients per year will be recruited for the study. Cell surface phenotype, including percentage of cells with T4 and T8 and dual staining T8-Leu 7, T8-T10, and T8-Dr, and relative immune responses to PHA, con A, pokeweed mitogen and allogeneic cells, will be assessed at least 3 times per year for each patient. Data from clinical studies relating to skin test responses will also be incorporated into the analyses.